Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
CU6 Stock Chart & Stats
AU$3.57
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$3.57
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.43 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$1.06B
Enterprise ValueAU$1.28B
Total Cash (Recent Filing)AU$84.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Mar 04, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding372,030,060
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$5.70Price Target Upside59.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers financial risk and interest expense, giving Clarity structural flexibility to fund clinical programs or pursue partnerships without near-term debt obligations. This enhances strategic optionality and reduces bankruptcy/default risk versus leveraged peers over the medium term.
High Gross Margin ProfileA near-100% gross margin reflects strong product-level economics typical of radiopharmaceuticals. If the pipeline advances to commercialization, this structural margin advantage can enable rapid unit economics improvement and support scalable profitability once operating expenses moderate or are offset by revenue growth.
Focused Theranostics PipelineConcentrated focus on copper-based theranostics places the company in a structural growth niche within oncology diagnostics and targeted therapeutics. Specialized expertise and a clinical-stage pipeline can attract partnerships, long development-tail value and regulatory pathways that remain relevant beyond short-term cycles.
Bears Say
Widening LossesPersistently deep and widening losses indicate a structural gap between operating costs and revenues. Continued negative earnings erode equity over time, force management to prioritize fundraising over value-creating activities, and increase execution risk for expensive clinical development programs.
Consistent Cash BurnSustained negative operating and free cash flow, with rising outflows in 2025, create a structural funding need. Ongoing cash burn heightens dependence on external capital, risks dilutive financings, and can constrain the timing or scope of clinical and commercial activities if capital markets tighten.
Declining Equity / Dilution RiskA materially falling equity base reduces the balance-sheet buffer and increases the likelihood of dilutive capital raises. Combined with ongoing losses, declining equity weakens negotiating leverage with partners and raises the probability of dilution-driven shareholder value erosion over the medium term.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.43 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$1.06B.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 14 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.12 earnings per share for the quarter, missing the consensus estimate of -AU$0.079 by -AU$0.041.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.08.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,030,060 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.12 in its last earnings report, missing expectations of -AU$0.079. Following the earnings report the stock price went down -7.558%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$5.70 (59.66% Upside)
AU$5.70 (59.66% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 91%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-54.37%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$5.70
▲(59.66% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---